According to the American Cancer Society, prostate cancer is the most common type of cancer found in American men, other than skin cancer.
Immunotherapy is the new black when it comes to treating Cancer, raising hope in conquering this age old illness.
The 5th Annual Vaccine Industry Excellence Awards has named Advaxis as the Best Therapeutic Vaccine for the company’s ADVX-HPV construct.
The company has been selected for the shortlist of the 5th Annual Vaccine Industry Excellence (ViE) Awards in the category of Best Therapeutic Vaccine.
BREAKING NEWS: Advaxis Reports Preliminary Safety and Survival Data from a Phase 2 Trial in Recurrent/Refractory Cervical Cancer
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies.
OneMedRadio interviewed Tom Moore, CEO and Chairman of the Board of Directors of Advaxis [OTC:ADXS]. He discusses the company’s novel immunotherapy technology.